AVITA Medical Q4 revenue down 4% to $17.6M; FY2026 guidance $80-85M

AVITA Medical, Inc.

2025-FY EPS reported -$1.74 revenue$71,610,000

Q4 revenue $17.6M (down 4% YoY); gross margin 81.2% vs 87.6%; net loss $11.6M ($0.38/sh) vs $11.6M ($0.44/sh).
Full-year 2025 revenue $71.6M (+11% YoY); net loss $48.6M ($1.74/sh) vs $61.8M ($2.39/sh) in 2024.
Net cash use improved to $5.1M in Q4; cash & marketable securities $18.2M at year-end.
New $60M credit facility with Perceptive Advisors; initial $50M funded, used to repay existing debt.
FY2026 revenue guidance $80-85M (12-19% growth); Cohealyx & PermeaDerm trials fully/significantly enrolled.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.